{
  "docId": "019de076-9d2b-76a8-843e-6686f2efe993",
  "docSlug": "264dd70dbc5f8f6fdd2a3dbf6f8c09b5",
  "documentTitle": "Exscientia | Investor Day Presentation Deck | 90 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 47,
  "pageCount": 90,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": "The slide uses a human anatomy diagram to map specific cancer types to their respective organs, providing a visual representation of the addressable market.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9d2b-76a8-843e-6686f2efe993/47",
  "deckHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993",
  "deckJsonHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993.json",
  "deckAnchorHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Covers all indications included in Ph1/2 ELUCIDATE trial; Patient counts for each subtype based on EvaluatePharma Epidemiology 2022 and primary inclusion criteria for ELUCIDATE Ph 1/2 trial. Treatment rate and progression rates based on Cerner Enviza Treatment Architecture Reports 2022; Numbers have been rounded to the nearest 1000 patients per year; *Excludes currently actionable driver mutations such as ALK, EGFR, BRAF, ROS1, RET and MET",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62da6d78-53b1-4e8e-9a7e-005e96deb0bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.95,
        "w": 0.35,
        "x": 0.18,
        "y": 0.05
      },
      "kind": "image",
      "text": "Human anatomy diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84aa64ea-336c-4cee-9165-d77921f46aeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.6,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "list",
      "text": "5K Head & Neck Cancer; 29K Non-small Cell Lung Cancer; 6K Ovarian Cancer; 12K Breast Cancer; 8K Pancreatic Cancer; 15K Colorectal Cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bc3c6de-2665-4a3a-842c-cd8e1b368a82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.68,
        "y": 0.45
      },
      "kind": "metric",
      "text": "~75K U.S. Patients Lives Annually",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9df904a-f69f-49a3-869e-312d5e97116a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "2022 United States incidence for patient sub-groups included in ELUCIDATE trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81fb20f4-078c-464f-b00e-a6e8aecfe447",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6459525f-5e96-4bd0-a17e-62a46e82489b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-sizing",
      "slug": null,
      "matchId": "d2501379-3a94-44bf-9d6b-990a838e32f1",
      "evidence": "Breakdown of total addressable patient population by sub-segment",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 90,
      "from": 21,
      "beatId": "08c298bd-8dc4-4aa8-832d-c7b35097d152",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The presentation deck ends with a call to action, encouraging investors to take action",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}